99 related articles for article (PubMed ID: 8469900)
1. [Therapeutic perspectives of severe infectious states].
Offenstadt G; Guidet B; Barakett V
Rev Prat; 1993 Jan; 43(1):59-64. PubMed ID: 8469900
[TBL] [Abstract][Full Text] [Related]
2. Current prospects for the treatment of clinical sepsis.
Suffredini AF
Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188
[TBL] [Abstract][Full Text] [Related]
3. Sepsis and septic shock.
Zanetti G; Baumgartner JD; Glauser MP
Schweiz Med Wochenschr; 1997 Mar; 127(12):489-99. PubMed ID: 9106949
[TBL] [Abstract][Full Text] [Related]
4. Antiendotoxin therapies for septic shock.
Corriveau CC; Danner RL
Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy of severe infectious states].
Offenstadt G; Guidet B; Lazard T
Chirurgie; 1992; 118(10):601-6. PubMed ID: 1345691
[TBL] [Abstract][Full Text] [Related]
6. Endotoxin as a therapeutic target in septic shock.
Corriveau CC; Danner RL
Infect Agents Dis; 1993 Feb; 2(1):35-43. PubMed ID: 8162352
[TBL] [Abstract][Full Text] [Related]
7. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
Baudo F; de Cataldo F
Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
[TBL] [Abstract][Full Text] [Related]
8. [Latest results of intensive care of sepsis, septic shock and multiple organ injuries].
Incze F
Orv Hetil; 1999 Mar; 140(10):515-20. PubMed ID: 10323066
[TBL] [Abstract][Full Text] [Related]
9. [Corticotherapy in severe infectious states].
Annane D; Sharshar T; Auriant I; Clair B; Raphael JC; Gajdos P
Bull Acad Natl Med; 2000; 184(8):1631-40; discussion 1640-2. PubMed ID: 11471384
[TBL] [Abstract][Full Text] [Related]
10. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
Balk RA
Dis Mon; 2004 Apr; 50(4):168-213. PubMed ID: 15133467
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence.
Escames G; Acuña-Castroviejo D; López LC; Tan DX; Maldonado MD; Sánchez-Hidalgo M; León J; Reiter RJ
J Pharm Pharmacol; 2006 Sep; 58(9):1153-65. PubMed ID: 16945173
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Novel potential therapies for septic shock.
Azevedo LC; Park M; Schettino GP
Shock; 2008 Oct; 30 Suppl 1():60-6. PubMed ID: 18704007
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy of sepsis and septic shock].
Ivanović D; Gjurasin M; Gasparović V; Radonić R; Kvarantan M; Merkler M
Lijec Vjesn; 1995 Jun; 117 Suppl 2():8-11. PubMed ID: 8649167
[TBL] [Abstract][Full Text] [Related]
15. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.
Opal SM
Int J Med Microbiol; 2007 Sep; 297(5):365-77. PubMed ID: 17452016
[TBL] [Abstract][Full Text] [Related]
16. Treatment of septic shock with immunotherapy.
Smith AL
Pharmacotherapy; 1998; 18(3):565-80. PubMed ID: 9620107
[TBL] [Abstract][Full Text] [Related]
17. The current management of septic shock.
Russel JA
Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacotherapy of sepsis].
Guzzo I; Morabito S; Stucchi R; Poli G; Fumagalli R
G Ital Nefrol; 2006; 23 Suppl 36():S79-86. PubMed ID: 17068734
[TBL] [Abstract][Full Text] [Related]
19. New strategies for combatting sepsis: the magic bullets missed the mark ... but the search continues.
Quezado ZM; Banks SM; Natanson C
Trends Biotechnol; 1995 Feb; 13(2):56-63. PubMed ID: 7765996
[TBL] [Abstract][Full Text] [Related]
20. Anti-endotoxin antibodies and other inhibitors of endotoxin.
Zanetti G; Glauser MP; Baumgartner JD
New Horiz; 1993 Feb; 1(1):110-9. PubMed ID: 7922383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
